Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DTEB | ISIN: CH0363463438 | Ticker-Symbol: 19T
Lang & Schwarz
04.11.24
22:58 Uhr
1,027 Euro
+0,032
+3,24 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IDORSIA AG Chart 1 Jahr
5-Tage-Chart
IDORSIA AG 5-Tage-Chart
RealtimeGeldBriefZeit
1,0091,04504.11.
0,0000,00028.03.23

Aktuelle News zur IDORSIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoDeutsche Bank stuft Idorsia auf "Halten" hoch, setzt Kursziel bei 1,00 CHF12
MoDeutsche Bank raises Idorsia to Hold, sets CHF1.00 target5
MoIdorsia, Also und weitere: Grosser Tag der Aktienumstufungen13
29.10.Neurocrine, Idorsia part ways 2 years after collab's double phase 2 fails55
29.10.Idorsia erwartet für das Gesamtjahr kleineren Verlust435Allschwil - Idorsia schreibt in den ersten neun Monaten weiterhin tiefroste Zahlen. Mit dem Hoffnungsträger Quviviq hat das angeschlagene Biotechunternehmen aber mehr Umsatz gemacht. Der Verlust im...
► Artikel lesen
29.10.Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first nine months of 2024282Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net...
► Artikel lesen
16.10.Idorsia Pharmaceuticals Ltd: New data on aprocitentan to be presented at the ASN Kidney Week 2024383Allschwil, Switzerland - October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia's endothelin receptor antagonist, will be presented at the American Society...
► Artikel lesen
17.09.Idorsia Pharmaceuticals Ltd: Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024484Allschwil, Switzerland - September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults...
► Artikel lesen
05.09.Idorsia Pharmaceuticals Ltd: New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024437Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland - September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan...
► Artikel lesen
02.09.Idorsia Pharmaceuticals Ltd: Amended terms of Idorsia's 2024 convertible bonds become effective764Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period - during which no...
► Artikel lesen
25.07.Idorsia reports 1H results38
25.07.Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first half 2024757Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights Viatris...
► Artikel lesen
18.07.Idorsia Pharmaceuticals Ltd: Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call420Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day. Date:...
► Artikel lesen
01.07.European Commission Approves Idorsia's JERAYGO For Resistant Hypertension Treatment7
01.07.Idorsia Pharmaceuticals Ltd: Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension451Idorsia receives approval from the European Commission (EC) for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...
► Artikel lesen
28.06.Idorsia Pharmaceuticals Ltd: Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds680Allschwil, Switzerland - June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale Nachlassbehörde)...
► Artikel lesen
25.06.Idorsia Pharmaceuticals Ltd: Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds425Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...
► Artikel lesen
21.06.Idorsia Pharmaceuticals Ltd: Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the 'Primary & Speciality' category601Idorsia's dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize...
► Artikel lesen
13.06.Idorsia Pharmaceuticals Ltd: Idorsia holds its Annual General Meeting of Shareholders1.978All Board proposals approved by the shareholders Allschwil, Switzerland - June 13, 2024At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders...
► Artikel lesen
03.06.Idorsia Pharmaceuticals Ltd: New data with daridorexant to be presented at SLEEP 2024683Allschwil, Switzerland - June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with insomnia...
► Artikel lesen
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4